Omalizumab
Omalizumab increases thresholds for reactions in multiple food allergies
WASHINGTON — Omalizumab increased thresholds for reacting to peanut and other common allergenic foods during accidental exposure, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Q&A: Omalizumab provides protective effect for multiple food allergies
WASHINGTON — Patients with multiple food allergies experienced a protective effect against allergic reactions with omalizumab, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
VIDEO: Omalizumab gives families with food allergy ‘some hope’ for normal lives
WASHINGTON — Robert Wood, MD, FAAAAI, recounted the results of the OUtMATCH study to a standing-room-only crowd at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Q&A: FDA-approved omalizumab ‘not a cure’ for food allergy
The FDA has approved omalizumab for use in building tolerance to accidental ingestion of allergens among patients with IgE-mediated food allergy.
Better application of biologics may lead to asthma remission, prevention
ANAHEIM, Calif. — The use of biologics for asthma will grow as physicians better define who will respond to specific treatments, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Top in allergy/asthma: Food allergy treatment; new practice parameters
The FDA has granted priority review to omalizumab as a treatment for food allergy after accidental exposure, according to a press release.
FDA grants priority review to omalizumab in treatment of food allergy
The FDA has accepted a supplemental biologics application for the use of omalizumab to reduce allergic reactions due to accidental exposure in patients aged 1 year and older with at least one food allergy, according to a press release.
Chronic spontaneous urticaria remains uncontrolled with antihistamine treatment
ANAHEIM, Calif. — A high proportion of chronic spontaneous urticaria cases remained uncontrolled despite antihistamine changes, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Patients with well-controlled chronic urticaria may halt omalizumab treatment
Some patients who use omalizumab to treat their chronic urticaria may discontinue its use to reveal disease remission and avoid drug exposure, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Omalizumab efficacy for asthma similar among children of different races
Children with asthma aged 6 years to younger than 12 years had similar reductions in exacerbations with omalizumab regardless of race, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.